XML 31 R33.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Stock-Based Compensation Stock-Based Compensation (Details) (USD $)
3 Months Ended 6 Months Ended
Jun. 30, 2011
years
Jun. 30, 2010
Jun. 30, 2011
years
Jun. 30, 2010
Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Directors' Fees in Stock-Based Compensation $ (258,000) $ (166,000) $ (515,000) $ (333,000)  
Total Stock-Based Compensation 2,509,000 1,604,000 5,010,000 3,199,000  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]          
Stock Options, Outstanding, Beginning Balance 391,542   391,542   442,880
Stock Options, Exercised     12,561    
Stock Options, Forfeited     26,754    
Stock Options, Expired     12,023    
Stock Options, Outstanding, Ending Balance 391,542   391,542   442,880
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]          
Stock Options, Vested and Expected to Vest 391,542   391,542    
Stock Options, Exercisable 391,542   391,542    
Stock Options, Outstanding, Weighted Average Exercise Price, Beginning Balance     $ 51.85    
Stock Options, Exercised, Weighted Average Exercise Price $ 35.61   $ 35.61    
Stock Options, Forfeited, Weighted Average Exercise Price $ 51.43   $ 51.43    
Stock Options, Expired, Weighted Average Exercise Price     $ 60.18    
Stock Options, Outstanding, Weighted Average Exercise Price, Ending Balance $ 52.14   $ 52.14    
Stock Options, Vested and Expected to Vest, Weighted Average Exercise Price $ 52.14   $ 52.14    
Stock Options, Exercisable, Weighted Average Exercise Price $ 52.14   $ 52.14    
Stock Options, Outstanding, Weighted Average Remaining Contractual Term in Years, Beginning Balance     3.5    
Stock Options, Outstanding, Weighted Average Remaining Contractual Term in Years, Ending Balance 3.5   3.5    
Stock Options, Vested and Expected to Vest, Weighted Average Remaining Contractual Term in Years     3.5    
Stock Options, Exercisable, Weighted Average Remaining Contractual Term in Years     3.5    
Stock Options, Outstanding, Aggregate Intrinsic Value, Beginning Balance     (4,255,000)    
Stock Options, Outstanding, Aggregate Intrinsic Value, Ending Balance (3,200,000)   (3,200,000)    
Stock Options, Vested and Expected to Vest, Aggregate Intrinsic Value (3,200,000)   (3,200,000)    
Stock Options, Exercisable, Aggregate Intrinsic Value (3,200,000)   (3,200,000)    
Stock Options, Non-Vested, Outstanding, Beginning Balance     2,185    
Stock Options, Vested     2,185    
Stock Options, Non-Vested, Outstanding, Ending Balance 0   0    
Non-Vested Stock Options, Weighted Average Grant Date Fair Value, Beginning     $ 8.78    
Non-Vested Stock Options, Weighted Average Grant Date Fair Value, Ending $ 0.00   $ 0.00    
Stock Options Vested, Weighted Average Grant Date Fair Value     $ 8.78    
Director [Member]
         
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Restricted Stock in Stock-Based Compensation 72,000 57,000 134,000 106,000  
Parent Company [Member]
         
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Total Stock-Based Compensation     5,010,000 3,199,000  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]          
Restricted Stock, Non-Vested, Unrecognized Compensation Cost 19,000,000   19,000,000    
Partnership Interest [Member]
         
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Total Stock-Based Compensation     5,010,000 3,199,000  
Restricted Stock [Member]
         
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Restricted Stock in Stock-Based Compensation 2,695,000 1,713,000 5,391,000 3,426,000  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]          
Restricted Stock, Non-Vested, Shares Outstanding, Beginning Balance     436,559    
Restricted Stock, Shares Vested and Distributed     171,292    
Restricted Stock, Shares Forfeited     79    
Restricted Stock, Non-Vested, Shares Outstanding, Ending Balance 575,262   575,262    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]          
Restricted Stock, Non-Vested, Intrinsic Value 25,294,000   25,294,000    
Restricted Stock, Shares Vested and Distributed, Weighted Average Grant Price     $ 43.08    
Restricted Stock, Shares Forfeited, Weighted Average Grant Price $ 63.26   $ 63.26    
Restricted Stock, Shares Granted, Total Weighted Average Grant Price $ 41.79   $ 41.79    
Restricted Stock, Vested, Intrinsic Value $ 7,500,000   $ 7,500,000    
Time Based Awards Granted [Member]
         
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]          
Restricted Stock, Shares Granted     126,139    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]          
Restricted Stock, Shares Granted, Weighted Average Grant Price     $ 42.15    
Performance Based Awards Granted [Member]
         
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]          
Restricted Stock, Shares Granted     18,246    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]          
Restricted Stock, Shares Granted, Weighted Average Grant Price     $ 41.54    
Market Based Awards Granted [Member]
         
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]          
Restricted Stock, Shares Granted     165,689    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]          
Restricted Stock, Shares Granted, Weighted Average Grant Price     $ 41.54